Pea Protein Market worth $2.59 billion by 2031- Exclusive Report by MarketsandMarkets™

The global pea protein market is projected to grow from $1.45 billion in 2026 to $2.59 billion by 2031, representing a 12.3% CAGR, driven by demand for plant-based, clean-label and high-protein food and beverage products. Textured pea protein is forecast to grow fastest by type at a 12.8% CAGR, while beverages are expected to be the fastest-growing application and Asia-Pacific the fastest-growing region. The market remains fragmented, with the top five suppliers controlling an estimated 30%-35% of global share.

Analysis

This is not a material earnings driver for ADM or INGR on a standalone basis: even strong category growth is diluted within broad agricultural-processing and specialty-ingredients portfolios. The investable implication is mix, not volume—customers will pay for neutral taste, dispersion, emulsification and texture performance, shifting bargaining power toward formulation/IP providers rather than commodity pea processors. IFF is comparatively better positioned where high-moisture extrusion and flavor-masking solutions can attach higher-margin systems sales to protein demand; its exposure should be assessed through Food & Beverage Solutions organic growth and margin rather than pea-protein volumes.

Over the next 1-3 months, this press-release forecast is unlikely to alter consensus estimates or trigger a durable rerating. A more relevant catalyst is evidence that beverage and active-nutrition launches convert into repeat orders, because these formats can support premium ingredient pricing and higher utilization without depending on the still-volatile plant-based-meat channel. For ADM and INGR, incremental demand could improve specialty-ingredient plant utilization, but any benefit is vulnerable to pea-crop inflation, customer reformulation toward soy/fava/whey, and retailer rationalization of slow-turning plant-based SKUs.

The contrarian view is that the market is likely over-crediting broad plant-based consumption as the demand engine. The more durable profit pool may be protein fortification in conventional beverages, bars and healthy-aging products, where the ingredient is functional rather than identity-defining and consumer willingness to pay is less tied to vegan demand. Conversely, a fragmented supplier base limits sustainable pricing unless a supplier owns application know-how or has contracted capacity; headline market-growth estimates alone do not justify a sector beta trade.

Structural upside over 6-18 months accrues to suppliers able to monetize formulation bundles across regions, while basic concentrates remain exposed to agricultural input volatility and capacity additions. Monitor IFF’s segment margin and innovation-led sales, ADM/INGR specialty volumes and pricing, and new product velocity in protein RTD channels; these are the falsifiable indicators of mix-led earnings leverage.

Key Decisions for Investors

• Maintain a selective long bias in IFF versus ADM through the next 2-3 earnings cycles: use a long IFF / short ADM pair only if IFF’s valuation premium remains below its expected Food & Beverage Solutions margin inflection. Thesis target is relative outperformance on higher-value formulation mix; exit if IFF organic growth or segment margin misses guidance for two consecutive quarters.
• Do not initiate a directional ADM or INGR position from this item. Set an alert for disclosed specialty-protein volume growth above company-wide volumes and positive price/mix for two quarters; absent that evidence, category growth is too small and too commoditized to move consolidated EPS.
• For higher-risk exposure, place BU (Burcon) on a watchlist rather than buying: an investable catalyst requires independently verified commercial offtake, funded scale-up capacity and gross-margin disclosure. Without those, technology optionality remains vulnerable to dilution and commercialization delays.
• Watch pea and competing protein input spreads over the next 6-12 months. A sustained widening versus soy/whey would pressure customer reformulation and invalidate the premiumization thesis; improving utilization and stable gross margins at IFF/INGR would be the confirming signal.